travoprost and Inflammation

To evaluate the efficacy and safety of travoprost 0.004% versus timolol 0.5% as an initial intraocular pressure (IOP)-lowering medication for ocular hypertension secondary to vitrectomy.. We performed a randomized, controlled, observer-blinded clinical trial in the Eye & ENT Hospital of Fudan University in China. This trial was registered at www.chictr.org.cn (ChICTR1800014942) before patient enrollment. Seventy-nine adults with IOP of 25-45 mmHg secondary to vitrectomy in the latest one month were enrolled and randomized to receive travoprost 0.004% or timolol 0.5%. More drugs were administered to patients with IOP > 25 mmHg during follow-up.. The mean IOP reduction at day 1 was -10.97 mmHg in the timolol group and -15.02 mmHg in the travoprost group (. Travoprost and timolol have similar efficacy and safety for treating ocular hypertension secondary to vitrectomy.

Topics: Female; Humans; Inflammation; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Risk Factors; Single-Blind Method; Timolol; Travoprost; Vitrectomy